Area of research
Molecular Biology · Physiology
Research interest
Research interests include Lysosomal Storage Disorders Research, Ion Transport and Channel Regulation, Ion channel regulation and function, and Electrolyte and hormonal disorders.
A phase <scp>III</scp>, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study
Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study
Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm
Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus
Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney Injury
Use of a rare disease registry for establishing phenotypic classification of previously unassigned <i>GLA</i> variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup
Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
Current and Investigational Therapeutics for Fabry Disease
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial
Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study
Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints
Serum albumin concentration and risk of end-stage renal disease: the REGARDS study
Conjunctival lymphangiectasia associated with classic Fabry disease
The global burden of chronic kidney disease: estimates, variability and pitfalls
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry
Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults
Estimated Glomerular Filtration Rate: Fit for What Purpose?